Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

RAS-targeted therapies: is the undruggable drugged?
Amanda R. Moore, Scott Rosenberg, Frank McCormick, et al.
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 8, pp. 533-552
Open Access | Times Cited: 810

Showing 26-50 of 810 citing articles:

Cancer gene mutation frequencies for the U.S. population
Gaurav Mendiratta, Eugene Ke, Meraj Aziz, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 135
Exosome-mediated delivery of CRISPR/Cas9 for targeting of oncogenic KrasG12D in pancreatic cancer
Kathleen M. McAndrews, Fei Xiao, Antonios Chronopoulos, et al.
Life Science Alliance (2021) Vol. 4, Iss. 9, pp. e202000875-e202000875
Open Access | Times Cited: 134
The KRAS-G12C inhibitor: activity and resistance
Jiao Liu, Rui Kang, Daolin Tang
Cancer Gene Therapy (2021) Vol. 29, Iss. 7, pp. 875-878
Open Access | Times Cited: 129
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Chunxiao Zhu, Xiaoqing Guan, Xinuo Zhang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 128
Recent advances in non-small cell lung cancer targeted therapy; an update review
Mahmood Araghi, Reza Mannani, Ali Heidarnejad maleki, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 127
The RASopathies: from pathogenetics to therapeutics
Katie E. Hebron, Edjay R. Hernandez, Marielle E. Yohe
Disease Models & Mechanisms (2022) Vol. 15, Iss. 2
Open Access | Times Cited: 115
Fragment-based covalent ligand discovery
Wenchao Lu, Milka Kostić, Tinghu Zhang, et al.
RSC Chemical Biology (2021) Vol. 2, Iss. 2, pp. 354-367
Open Access | Times Cited: 106
Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers
Martha Dillon, Antonio R. Lopez, Edward H. Lin, et al.
Cancers (2021) Vol. 13, Iss. 20, pp. 5059-5059
Open Access | Times Cited: 105
Chemoselective Covalent Modification of K-Ras(G12R) with a Small Molecule Electrophile
Ziyang Zhang, Johannes Morstein, Andrew K Ecker, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 35, pp. 15916-15921
Open Access | Times Cited: 91
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Matthew Holderfield, Bianca J. Lee, Jingjing Jiang, et al.
Nature (2024) Vol. 629, Iss. 8013, pp. 919-926
Open Access | Times Cited: 90
Small molecule inhibitors targeting the cancers
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 87
KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy
Meagan B. Ryan, Oluwadara Coker, Alexey V. Sorokin, et al.
Cell Reports (2022) Vol. 39, Iss. 12, pp. 110993-110993
Open Access | Times Cited: 86
Peptides as multifunctional players in cancer therapy
Sri Murugan Poongkavithai Vadevoo, Smriti Gurung, Hyun‐Su Lee, et al.
Experimental & Molecular Medicine (2023) Vol. 55, Iss. 6, pp. 1099-1109
Open Access | Times Cited: 84
Drugging KRAS: current perspectives and state-of-art review
Kaushal Parikh, Giuseppe Luigi Banna, Stephen V. Liu, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 83
KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
Chengming Liu, Sufei Zheng, Zhanyu Wang, et al.
Cancer Communications (2022) Vol. 42, Iss. 9, pp. 828-847
Open Access | Times Cited: 78
KRAS is vulnerable to reversible switch-II pocket engagement in cells
James D. Vasta, D. Matthew Peacock, Qinheng Zheng, et al.
Nature Chemical Biology (2022) Vol. 18, Iss. 6, pp. 596-604
Open Access | Times Cited: 75
Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor
Mikimasa Tanada, Minoru Tamiya, Atsushi Matsuo, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 30, pp. 16610-16620
Closed Access | Times Cited: 73
KLF4 transcription factor in tumorigenesis
Zhihong He, Jie He, Keping Xie
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 68
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Jingjing Jiang, Lingyan Jiang, Benjamin J. Maldonato, et al.
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 994-1017
Open Access | Times Cited: 68
miRNAs role in bladder cancer pathogenesis and targeted therapy: Signaling pathways interplay – A review
Hesham A. El-Mahdy, Elsayed G.E. Elsakka, Ahmed A. El-Husseiny, et al.
Pathology - Research and Practice (2023) Vol. 242, pp. 154316-154316
Closed Access | Times Cited: 59
Methods and biomarkers for early detection, prediction, and diagnosis of colorectal cancer
Yue Zhang, Yin Wang, Bingqiang Zhang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 163, pp. 114786-114786
Open Access | Times Cited: 56
Dynamic regulation of RAS and RAS signaling
Walter Kölch, Dénes Berta, Edina Rosta
Biochemical Journal (2023) Vol. 480, Iss. 1, pp. 1-23
Open Access | Times Cited: 53
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Jayesh Desai, Guzmán Alonso, Se Hyun Kim, et al.
Nature Medicine (2023) Vol. 30, Iss. 1, pp. 271-278
Open Access | Times Cited: 53
Annual review of PROTAC degraders as anticancer agents in 2022
Xiao Wang, Zhao-Long Qin, Na Li, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116166-116166
Closed Access | Times Cited: 53
State-specific protein–ligand complex structure prediction with a multiscale deep generative model
Zhuoran Qiao, Weili Nie, Arash Vahdat, et al.
Nature Machine Intelligence (2024) Vol. 6, Iss. 2, pp. 195-208
Closed Access | Times Cited: 47

Scroll to top